ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor‐tyrosine kinase inhibitor, enhances the anti‐cancer effects of TRAIL in human esophageal squamous cell carcinomaFuminori Teraishi, Toshiyoshi Fujiwara|FEBS Letters|2005Cited by 64
Impact of the endoscopic surgical skill qualification system on conversion to laparotomy after low anterior resection for rectal cancer in Japan (a secondary analysis of the EnSSURE study)Koki Goto, Manabu Takata, Heita Ozawa et al.|Surgical Endoscopy|2024Cited by 8